TL;DR
Turn your quiet moments into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Recent approvals of lecanemab and donanemab mark a significant breakthrough in Alzheimer’s treatment, slowing cognitive decline. Experts say science is shifting towards more effective, targeted therapies, but challenges and uncertainties remain.
Two new drugs, lecanemab and donanemab, approved in 2023, are now available to treat early-stage Alzheimer’s disease, marking a major shift in the field. These treatments can slow cognitive decline in patients with mild symptoms, offering tangible progress after decades of stagnation. Experts say this represents a significant breakthrough in Alzheimer’s care, but the treatments are not cures and come with risks.
The approval of lecanemab (sold as Leqembi) and donanemab (Kisunla) has transformed the landscape of Alzheimer’s treatment. Both drugs target amyloid plaques in the brain, a hallmark of the disease, and are administered via intravenous infusion. They are effective primarily for patients in early stages—those with mild cognitive impairment—and can only slow disease progression, not reverse or stop it entirely. While these drugs have shown promise, they carry risks such as brain bleeds and swelling, which require careful monitoring.
Prior to these approvals, there had been little progress in disease-modifying treatments for decades, with existing medications only managing symptoms temporarily. The new drugs are part of a broader shift in research, which now considers multiple mechanisms beyond amyloid buildup, including tau protein accumulation and inflammation. Several other drugs targeting these mechanisms are currently in clinical trials, indicating a more diversified approach to tackling Alzheimer’s.
Researchers emphasize that these developments do not mean Alzheimer’s is now curable or fully manageable. Instead, they represent a crucial step forward, providing hope for patients and families and encouraging further innovation in the field.
Why New Alzheimer’s Treatments Matter Now
The recent drug approvals signify a paradigm shift in Alzheimer’s research and care. For the first time in decades, treatments are available that can slow disease progression, offering tangible benefits to patients in early stages. This progress could lead to improved quality of life, reduced caregiver burden, and a new framework for developing more effective therapies. However, these drugs are not cures, and their risks mean they are not suitable for all patients. The shift also reflects a broader scientific consensus that multiple biological pathways contribute to Alzheimer’s, guiding future research toward more targeted and potentially more effective treatments.
Furthermore, the advances come amid a growing recognition that early detection—through blood tests and biomarkers—can enable earlier intervention, potentially delaying or preventing symptoms altogether. This integrated approach could fundamentally change how society perceives and manages Alzheimer’s disease, emphasizing prevention and personalized medicine.
Alzheimer's disease blood test kit
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Evolution of Alzheimer’s Research and Treatment
For many years, Alzheimer’s research was dominated by the amyloid hypothesis, which posited that amyloid plaques caused the disease’s cognitive decline. This led to decades of drug development focused on removing or reducing amyloid, but most efforts failed in clinical trials. The approval of aducanumab in 2021 marked a controversial milestone, with mixed evidence of efficacy and safety concerns.
In 2023, the approval of lecanemab and donanemab was based on more robust evidence of slowing cognitive decline in early-stage patients, signaling a shift toward targeting amyloid more effectively. Meanwhile, scientists are increasingly exploring other mechanisms, such as tau protein accumulation and neuroinflammation, which are now recognized as important contributors to the disease. Multiple drugs targeting these pathways are in clinical trials, reflecting a broader understanding of Alzheimer’s as a complex, multi-faceted condition.
This evolving view is supported by research showing that some individuals with amyloid buildup never develop symptoms, indicating that other factors influence disease progression. The scientific community now embraces a more nuanced approach, aiming for personalized treatments tailored to individual biological profiles.
“Diagnosis and treatment of Alzheimer’s has changed in a way that is revolutionary compared to, say, four or five years ago.”
— Dr. Jason Karlawish
cognitive health supplements for early memory loss
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Unresolved Questions and Challenges Ahead
Despite progress, many uncertainties remain. It is not yet clear how long the benefits of these drugs will last or whether they will be effective in more advanced stages of Alzheimer’s. The risks associated with side effects, such as brain swelling and bleeding, require careful management, and not all patients are suitable candidates.
Moreover, the long-term safety and real-world effectiveness of these treatments are still being studied. There is also ongoing debate about whether slowing decline is enough or if future therapies can fully halt or reverse the disease. The development of reliable early detection methods, such as blood tests, is promising but still evolving, and their integration into routine care is not yet widespread.
As an affiliate, we earn on qualifying purchases.
Next Steps in Alzheimer’s Research and Care
Researchers are now focusing on expanding the pipeline of therapies targeting multiple disease mechanisms, including tau and inflammation. Several drugs are in advanced clinical trials, aiming to improve efficacy and reduce side effects. The hope is that combination therapies could address the complexity of Alzheimer’s more effectively.
Simultaneously, efforts are underway to improve early diagnosis through blood tests and biomarkers, enabling interventions before significant cognitive decline occurs. Policymakers and healthcare providers are also working to integrate these new treatments into standard care, which will involve training, infrastructure, and patient education.
Finally, ongoing research aims to understand why some individuals with amyloid buildup do not develop symptoms, potentially unlocking new preventative strategies. The coming years will be critical in determining whether these scientific advances translate into widespread, effective treatments for Alzheimer’s disease.
Alzheimer's care infusion therapy supplies
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
Are the new drugs a cure for Alzheimer’s?
No, currently approved drugs like lecanemab and donanemab only slow the progression of early-stage Alzheimer’s. They are not cures and do not reverse existing damage.
What are the risks associated with these new treatments?
Risks include brain swelling and bleeding, which require careful monitoring by healthcare providers. Not all patients are suitable candidates for these therapies.
Can these treatments be used in later stages of Alzheimer’s?
Currently, these drugs are approved only for early-stage disease. Their effectiveness in advanced stages is not established and is a subject of ongoing research.
How soon might new therapies targeting tau or inflammation become available?
Several tau and inflammation-targeting drugs are in clinical trials, with some expected to reach late-stage testing within the next few years. However, approval depends on trial outcomes and regulatory review.
Will early detection methods become part of routine screening?
Blood tests and biomarkers for early detection are promising but are not yet standard practice. Wider adoption will depend on further validation and healthcare system integration.
Source: Vox
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
